EP4088721A4 - Composition de traitement du syndrome de l'x fragile ou des troubles du développement associés, comprenant un composé de lisuride en tant que principe actif - Google Patents

Composition de traitement du syndrome de l'x fragile ou des troubles du développement associés, comprenant un composé de lisuride en tant que principe actif

Info

Publication number
EP4088721A4
EP4088721A4 EP21738899.0A EP21738899A EP4088721A4 EP 4088721 A4 EP4088721 A4 EP 4088721A4 EP 21738899 A EP21738899 A EP 21738899A EP 4088721 A4 EP4088721 A4 EP 4088721A4
Authority
EP
European Patent Office
Prior art keywords
lisuride
syndrome
compound
composition
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21738899.0A
Other languages
German (de)
English (en)
Other versions
EP4088721A1 (fr
Inventor
Sohyun Joo
Chanyoung Shin
Sejin Jeon
Taejin Ahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuroventi
Original Assignee
Neuroventi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroventi filed Critical Neuroventi
Publication of EP4088721A1 publication Critical patent/EP4088721A1/fr
Publication of EP4088721A4 publication Critical patent/EP4088721A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP21738899.0A 2020-01-08 2021-01-08 Composition de traitement du syndrome de l'x fragile ou des troubles du développement associés, comprenant un composé de lisuride en tant que principe actif Pending EP4088721A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200002576 2020-01-08
PCT/KR2021/000227 WO2021141426A1 (fr) 2020-01-08 2021-01-08 Composition de traitement du syndrome de l'x fragile ou des troubles du développement associés, comprenant un composé de lisuride en tant que principe actif

Publications (2)

Publication Number Publication Date
EP4088721A1 EP4088721A1 (fr) 2022-11-16
EP4088721A4 true EP4088721A4 (fr) 2024-01-10

Family

ID=76788829

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21738899.0A Pending EP4088721A4 (fr) 2020-01-08 2021-01-08 Composition de traitement du syndrome de l'x fragile ou des troubles du développement associés, comprenant un composé de lisuride en tant que principe actif

Country Status (5)

Country Link
US (1) US20230024384A1 (fr)
EP (1) EP4088721A4 (fr)
KR (2) KR102528677B1 (fr)
CN (1) CN115335053A (fr)
WO (1) WO2021141426A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3195170A1 (fr) * 2020-10-16 2022-04-21 Georgios DRAKAKIS Compositions et utilisations associees

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2359128A1 (de) * 1973-11-24 1975-06-12 Schering Ag Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen
AU2007235232B2 (en) * 2006-04-06 2013-07-11 Nupathe Inc. Implants for the treatment of dopamine associated states
WO2008134123A1 (fr) 2007-04-30 2008-11-06 The Uab Research Foundation Ul97 utilisé pour traiter des troubles liés aux agrégats formés par les protéines
CA2834882C (fr) * 2010-11-11 2018-03-27 Sinoxa Pharma Gmbh Lisuride, terguride et leurs derives pour une utilisation dans la prophylaxie et/ou la therapie de modifications fibreuses
TW201606304A (zh) * 2013-09-09 2016-02-16 亞克柏拉有限公司 測定治療反應之方法
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
WO2018136600A1 (fr) * 2017-01-20 2018-07-26 Teva Pharmaceuticals International Gmbh Utilisation de pridopidine pour traiter le syndrome de l'x fragile

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHAFIQ SAMREEN ET AL: "Using antipsychotics for behavioral problems in children", EXPERT OPIN PHARMACOTHER, vol. 19, no. 13, 13 August 2018 (2018-08-13), London, UK, pages 1475 - 1488, XP093105595, ISSN: 1465-6566, DOI: 10.1080/14656566.2018.1509069 *

Also Published As

Publication number Publication date
KR102600350B1 (ko) 2023-11-09
WO2021141426A1 (fr) 2021-07-15
EP4088721A1 (fr) 2022-11-16
KR20210089595A (ko) 2021-07-16
KR20230023692A (ko) 2023-02-17
JP2023523119A (ja) 2023-06-02
KR102528677B1 (ko) 2023-05-04
CN115335053A (zh) 2022-11-11
US20230024384A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
EP4252853A3 (fr) Composés et compositions pour le traitement de troubles hématologiques
TN2011000222A1 (en) Melanocortin receptor agonists
EP3895717A4 (fr) Composition pharmaceutique pour prévenir ou traiter un cancer, comprenant weissella cibaria wikim28 en tant que substance active
MX2009011276A (es) Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.
EP2103214A4 (fr) Agent de traitement de sols ou de graines comprenant un composé quinoléine ou un sel de celui-ci en tant que substance active, ou procédé pour lutter contre une maladie de plante l'utilisant
IL286471A (en) The heteroaryl derivative, a method for its production and a pharmaceutical preparation containing it as an effective ingredient
WO2010121225A3 (fr) Méthodes de traitement de troubles liés à l'activité de la protéine kinase ck2
EP3572087A4 (fr) Composition destinée à la prévention ou au traitement de l'arthrose contenant comme principe actif du sialyllactose ou un sel correspondant
WO2007057748A3 (fr) Utilisation du colostrum pour la prophylaxie des syndromes grippaux
EP4108242A4 (fr) Composition pharmaceutique permettant de prévenir ou de traiter le cancer contenant un inhibiteur de signalisation mtor comme principe actif
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
EP3851099A4 (fr) Composition destinée à traiter des maladies fibrotiques, comprenant un composé benzhydryl thioacétamide en tant que principe actif
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
EP4088721A4 (fr) Composition de traitement du syndrome de l'x fragile ou des troubles du développement associés, comprenant un composé de lisuride en tant que principe actif
EP3620457A4 (fr) Composé dérivé de pyrimidine, isomère optique, ou sel pharmaceutiquement acceptable de celui-ci, et composition pour prévenir ou traiter une maladie liée au tyro 3 le comprenant en tant que principe actif
EP4066835A4 (fr) Utilisation d'une composition pour améliorer l'effet anticancéreux, comprenant un inhibiteur de err-gamma comme principe actif
EP3327001A4 (fr) Nouveau composé présentant une activité inhibitrice de blt et composition, destiné à prévenir ou à traiter des maladies inflammatoires, contenant ce dernier en tant que principe actif
EP3395804A4 (fr) Nouveau composé dérivé de spiroquinone, son procédé de production, et composition pharmaceutique le contenant en tant que principe actif pour prévenir ou traiter des troubles neurologiques
EP3964219A4 (fr) Composition pharmaceutique pour le traitement de la septicémie ou du syndrome de réponse inflammatoire systémique, comprenant des mitochondries isolées en tant que principe actif
EP3747435A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de complications du diabète comprenant un nouveau composé dérivé de chrysine en tant que principe actif
GB2579480B (en) Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient
EP4101448A4 (fr) Composition comprenant un composé de rilmenidine en tant que principe actif pour le traitement du syndrome de l'x fragile ou de la déficience développementale associée
EP3939988A4 (fr) Composition pharmaceutique comprenant un nouveau composé hétérocyclique azolopyrimidine en tant que principe actif
EP3711761A4 (fr) Utilisation d'un composé de carbamate pour atténuer ou traiter des troubles du développement comprenant le syndrome du x fragile, le syndrome d'angelman ou le syndrome de rett
EP3964218A4 (fr) Composition pharmaceutique destinée à prévenir ou traiter la myosite, comprenant des mitochondries isolées en tant que principe actif

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031473800

Ipc: A61K0031480000

A4 Supplementary search report drawn up and despatched

Effective date: 20231208

RIC1 Information provided on ipc code assigned before grant

Ipc: A23L 33/10 20160101ALI20231204BHEP

Ipc: A61P 25/00 20060101ALI20231204BHEP

Ipc: A61K 31/48 20060101AFI20231204BHEP